Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps

Corcept Therapeutics Incorporated (NASDAQ:CORT) stock is trading higher on Thursday, with a session volume of 3.06 million.The company’s ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer met its overall survival (OS) primary endpoint.DataIn ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 35% reduction in the risk of death compared to patients treated with nab-paclitaxel alone (hazard ratio: ...